ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1228
-0,01%
Bitcoin
69.968,06
-0,23%
Brent Oil
82,155
-0,35%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Catalyst Pharmaceuticals Inc (CPRX)

  7. Catalyst Pharmaceuticals Inc (CPRX) Notícias

CPRX

Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CPRX
DataHoraFonteTítuloCódigoCompanhia
21/05/202418:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202417:16GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/05/202417:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
01/05/202409:00GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
22/04/202409:00GlobeNewswire Inc.Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
28/03/202409:03GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness DayNASDAQ:CPRXCatalyst Pharmaceuticals Inc
27/03/202409:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy SymposiumNASDAQ:CPRXCatalyst Pharmaceuticals Inc
13/03/202408:55GlobeNewswire Inc.Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)NASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/03/202410:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:CPRXCatalyst Pharmaceuticals Inc
28/02/202420:03GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
27/02/202410:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREENASDAQ:CPRXCatalyst Pharmaceuticals Inc
21/02/202411:00GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal NeurologyNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/02/202419:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
14/02/202410:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
09/01/202418:05GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Closing of Public OfferingNASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/01/202419:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/01/202410:02GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:CPRXCatalyst Pharmaceuticals Inc
04/01/202418:49GlobeNewswire Inc.Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockNASDAQ:CPRXCatalyst Pharmaceuticals Inc
03/01/202419:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
18/12/202308:30GlobeNewswire Inc.Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo PharmaNASDAQ:CPRXCatalyst Pharmaceuticals Inc
15/12/202315:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/12/202318:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CPRXCatalyst Pharmaceuticals Inc
05/12/202310:03GlobeNewswire Inc.Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap CompaniesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
04/12/202310:03GlobeNewswire Inc.Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive PromotionsNASDAQ:CPRXCatalyst Pharmaceuticals Inc
16/11/202310:05GlobeNewswire Inc.Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:CPRXCatalyst Pharmaceuticals Inc
08/11/202318:11GlobeNewswire Inc.Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
02/11/202311:37GlobeNewswire Inc.Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®NASDAQ:CPRXCatalyst Pharmaceuticals Inc
30/10/202309:03GlobeNewswire Inc.Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education ExpoNASDAQ:CPRXCatalyst Pharmaceuticals Inc
26/10/202316:19GlobeNewswire Inc.Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera PharmaceuticalsNASDAQ:CPRXCatalyst Pharmaceuticals Inc
23/10/202309:03GlobeNewswire Inc.Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023NASDAQ:CPRXCatalyst Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CPRX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AMER3
Americanas ON
BOV
KRSA3
Kora Saude Participacoes... ON
BOV
COGN3
COGNA ON
BOV
BEEF3
MINERVA ON
BOV
IRBR3
IRB BRASIL ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados